Dianthus Therapeutics (DNTH) Common Equity (2017 - 2025)
Dianthus Therapeutics (DNTH) posted quarterly Common Equity of $493.4 million for Q4 2025, up 39.98% year-over-year from $352.5 million in Q4 2024, and down 9.71% quarter-over-quarter from $546.5 million in Q3 2025.
Dianthus Therapeutics (DNTH) Common Equity (2017 - 2025) Analysis & Trends
Dianthus Therapeutics' Common Equity history runs 9 years deep, the most recent figure standing at $493.4 million for Q4 2025.
- In Q4 2025, Common Equity rose 39.98% year-over-year to $493.4 million; the TTM figure through Dec 2025 stood at $493.4 million (up 39.98% YoY), while the FY2025 annual figure was $493.4 million, up 39.98% from the prior year.
- Common Equity for Q4 2025 stood at $493.4 million, down from $546.5 million in the prior quarter.
- The five-year high for Common Equity was $546.5 million in Q3 2025, with the low at -$61.5 million in Q2 2023.
- The 5-year median for Common Equity is $184.0 million (2021), against an average of $185.2 million.
- The sharpest annual moves came in 2022 and 2024: Common Equity sank 157.22% in 2022, then jumped 833.35% in 2024.
- Dianthus Therapeutics' Common Equity stood at -$17.2 million in 2021, then plunged by 157.22% to -$44.4 million in 2022, then surged by 480.61% to $168.9 million in 2023, then jumped by 108.73% to $352.5 million in 2024, then jumped by 39.98% to $493.4 million in 2025.
- Business Quant data shows DNTH's Common Equity at $493.4 million in Q4 2025, $546.5 million in Q3 2025, and $303.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Dianthus Therapeutics | 4.97 Bn | 4.57 Bn | - | 493.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 493.40 Mn |
| Sep 30, 2025 | 546.45 Mn |
| Jun 30, 2025 | 303.08 Mn |
| Mar 31, 2025 | 328.61 Mn |
| Dec 31, 2024 | 352.48 Mn |
| Sep 30, 2024 | 337.90 Mn |
| Jun 30, 2024 | 358.22 Mn |
| Mar 31, 2024 | 372.69 Mn |
| Dec 31, 2023 | 168.87 Mn |
| Sep 30, 2023 | 178.38 Mn |
| Jun 30, 2023 | -61.46 Mn |
| Mar 31, 2023 | -50.82 Mn |
| Dec 31, 2022 | -44.37 Mn |
| Sep 30, 2022 | -34.75 Mn |
| Jun 30, 2022 | -27.48 Mn |
| Mar 31, 2022 | -22.07 Mn |
| Dec 31, 2021 | -17.25 Mn |
| Sep 30, 2021 | 189.69 Mn |
| Jun 30, 2021 | 202.89 Mn |
| Mar 31, 2021 | 129.06 Mn |